Press Releases
November 7, 2022
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
November 2, 2022
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
October 19, 2022
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
September 14, 2022
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting
September 7, 2022
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference
August 24, 2022
Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase
August 3, 2022
Surface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022
August 1, 2022
Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference
June 29, 2022
Surface Oncology Appoints Carsten Brunn to Board of Directors
June 20, 2022
Surface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma
Displaying 1 - 10 of 26